Pulmonary Metastases in Urogenital Cancers; Surgical Treatment and Outcomes

Background Metastasis is remaining one of the major problems in cancer treatment. Like many other malignancies, urogenital tumors originating from kidney, prostate, testes, and bladder tend to metastasize to the lungs.The aim of this retrospective study is to evaluate the results of pulmonary metastasectomy in patients with primary urogenital tumors.Methods This study was approved by the local ethical committee. This study retrospectively analyses the patients who underwent lung resections for metastases in our department between 2002 and 2018. 22 out of 126 patients referred for pulmonary metastasectomy to our department had metastases from urogenital tumors.Demographic data and clinicopathological features were extracted from the medical records. Disease-free interval (DFI) was defined as the time between the first curative surgery and the detection of pulmonary metastasis. Results Among 22 patients who underwent lung metastasectomy consisted of 17 males and five females. Their metastasis originated from renal cell carcinoma (RCC; n = 9), bladder tumor (n = 7), testis tumors (n = 4), and prostate cancer (n = 2). There was no intraoperative complication. Postoperative complications were seen in 2 patients. Conclusions Although pulmonary metastases and its surgical management in various types of tumors is well known and documented, the data is limited to the role of the surgery for metastases of urogenital cancers on literature. Despite the limitations of this study, we aim to document our promising results of pulmonary metastasectomy in patients with primary urogenital tumors.Trial registration This study was approved by the local ethical committee (Registration number: 49109414-604.02 ; Date: 11/06/2019).

The antiproliferative action of the “early” protein of papillomavirus HPV16 E2 on testis toumors of mice induced by the injection of Hela cells

The аntiploliferative effect of the “early” protein of high-risk oncogenic human papillomavirus HPV16 E2 on mice testis tumors was discovered after the indyction that was happened after the intramuscular injection of cancer HeLa cells suspension. The regression of mice testis tumors was mostly dramatic during first 1-2 days after oral vaccination with HPV16 E2 (500 mg per mice) made in tomato plant expression system that was gradually decreasing to control variant. The typical monolayer of HeLa cells on the cultivation flask bottom was appeared after seeding of testis tissue cells on the DMEM medium they were only for 18% functionally active according to the detection by the staining with nitroblue tetrazolium and trypane blue.